The company stated, "Forward Pharma announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market notifying us that Nasdaq believes that Forward is a ‘public shell’ pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. SEC, which will remove Forward’s securities from listing and registration on The Nasdaq Stock Market. Additionally, we intend to file with the SEC a Form 15 requesting the suspension of Forward’s reporting obligations."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FWP:
- Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
- European Patent Offices’ EBA denies Forward’s EP2801355 petition for review
- Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
